MultiCell Technologies, Inc. (MCET)

0.0000 0.0000 (0.00%) As of 03:20PM EDT. Market open.

MultiCell Technologies, Inc.

68 Cumberland Street
Suite 301
Woonsocket, RI 02895
United States
401 762 0045

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2

Key executives

Name	Title	Pay	Exercised	Year born
Mr. W. Gerald Newmin	Chairman, CEO, President, CFO, Treasurer & Secretary	182.5k	N/A	1937
Ms. Barbara Corbett	Manager of Investor Relations	N/A	N/A	1948

Amounts are as of 31 December 2014, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.

Corporate governance

MultiCell Technologies, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.